Cardinal Health (CAH) Earnings Date & Reports

Key Takeaways

• Cardinal Health is scheduled to report fiscal first-quarter 2027 results on November 5, 2026, before the market opens.
• Wall Street consensus points to adjusted earnings per share (EPS) of roughly $2.92, up from $2.55 in the prior-year quarter.
• Consensus revenue expectations sit near $66.9 billion, compared with $64.0 billion a year earlier.
• Cardinal Health enters the print with a streak of four consecutive quarterly EPS beats.
• Investors will weigh results against the company's full-year fiscal 2027 guidance of $12.40 to $12.60 in non-GAAP EPS.

Earnings Context and Why It Matters

Cardinal Health (CAH) is a leading healthcare services and products company, anchored by its massive Pharmaceutical and Specialty Solutions distribution business. Its fiscal first-quarter results matter because they offer the first hard data point on whether the company can sustain the exceptional momentum it built during fiscal 2026, when revenue rose 14% to $254.2 billion and non-GAAP EPS climbed 37% to $11.26. The report also sets the tone for fiscal 2027, a year in which management is guiding to double-digit earnings growth even as it anticipates a normalization of the outsized pharmaceutical demand that lifted recent results. For investors, the print is a key test of execution and of the durability of growth across higher-margin specialty and other growth businesses.

Earnings Expectations

Analysts expect Cardinal Health to report adjusted EPS of approximately $2.92 for the fiscal first quarter, which represents growth of roughly 15% from $2.55 in the same period a year ago. Consensus revenue estimates cluster around $66.9 billion, up about 4.6% from $64.0 billion in the prior-year quarter. For the full fiscal year, the consensus EPS estimate stands near $12.55, in line with the upper half of management's guidance range of $12.40 to $12.60, which implies 13% to 15% growth.

Historically, Cardinal Health has been a reliable outperformer on the bottom line. The company has beaten consensus EPS expectations in each of its last four quarters, with beats ranging from roughly 11% to 20%. That track record raises the bar heading into this report, and investors will be watching whether the company can extend its streak while navigating a more normalized demand environment.

AI Screener

For traders and investors looking to identify opportunities beyond a single earnings event, Tickeron's AI Screener offers an AI-powered stock and ETF discovery tool designed to filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and emerging market opportunities more efficiently than manual screening. Consider exploring the AI Screener to complement your earnings-focused research with broader, data-driven market insights.

Market Reaction and Investor Sentiment

Sentiment heading into the fiscal first-quarter report is generally constructive. Cardinal Health shares have rallied strongly over the past year and recently reached record highs following an August earnings beat and an upbeat fiscal 2027 outlook that exceeded analyst forecasts. The company's status as a Dividend Aristocrat, with 29 consecutive years of dividend increases, and an aggressive capital-return program—including a $5 billion increase to its share repurchase authorization—have reinforced investor confidence.

Still, the bar is elevated. A streak of consecutive beats and a premium valuation leave limited room for disappointment. Key risk factors include the normalization of pharmaceutical demand after a strong fiscal 2026, ongoing tariff and input-cost pressures in the Global Medical Products and Distribution segment, and any signal that fiscal 2027 guidance may not be fully achievable. Investors will likely focus more on earnings quality and forward commentary than on the revenue line, which has missed estimates in recent quarters.

Forward Outlook and Key Factors to Monitor

Following the report, attention will turn to whether management reaffirms or adjusts its fiscal 2027 outlook. The company's guidance for 13% to 15% non-GAAP EPS growth assumes a more normalized demand environment than the outsized pharmaceutical activity seen in fiscal 2026. Commentary on brand and specialty pharmaceutical volumes, as well as generics program performance, will be closely parsed for signs of whether demand is tracking in line with those assumptions.

Investors should also watch the Global Medical Products and Distribution segment, where management has guided segment profit to $200 million to $220 million for the year. Input costs—including fuel and petroleum-based commodities—and foreign currency effects remain variables that could push results toward either end of that range. Management has signaled that this segment's profit is weighted toward the second half of the fiscal year.

Finally, integration progress on recent and announced tuck-in acquisitions, including Strive Medical and AdaptHealth's Diabetes Health business, and the continued scaling of specialty, at-home, and logistics businesses will be important indicators of whether growth can broaden beyond the core pharmaceutical distribution franchise. Execution against these priorities, rather than any single-quarter figure, will likely determine the trajectory of investor sentiment through fiscal 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations